Document Detail


Once-daily inhaled glucocorticosteroid administration in controlled asthma patients.
MedLine Citation:
PMID:  18479954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Inhaled glucocorticosteroids are usually administered in two equal daily doses. To simplify the method of treatment, once-daily administration has been used. However, little information regarding whether once-daily treatment can sufficiently control airway inflammation is available. We aimed to investigate whether once-daily administration of inhaled glucocorticosteroids can control airway inflammation. METHODS: Twenty-four well-controlled asthma patients were enrolled in a randomized crossover trial to compare the efficacies of once-daily and twice-daily administration of inhaled glucocorticosteroids. Initially, the patients were randomly assigned to receive either once-daily or twice-daily administration for 16 weeks. After an 8-week washout period, patients who originally received twice-daily administration were assigned to once-daily administration for 16 weeks and vice versa. We assessed the changes in the forced expiratory volume in 1s, morning and evening peak expiratory flows, asthma symptoms, health-related quality of life and fractional exhaled nitric oxide levels. RESULTS: Patients with once-daily administration showed the same level of clinical control and lung functions as patients receiving twice-daily administration. There was no difference in the fractional exhaled nitric oxide levels between the beginning and end of the twice-daily treatment (35.69 and 33.23ppb, respectively). In contrast, the fractional exhaled nitric oxide level was significantly higher at the end of the once-daily treatment (33.87 and 39.38ppb, respectively, p< 0.001). CONCLUSION: Although once-daily administration is sufficient for clinical control of asthma, it might not control airway inflammation sufficiently.
Authors:
Hirotsugu Hasegawa; Naoki Inui; Tomoyuki Fujisawa; Jun Sato; Hirotoshi Nakamura; Hiroshi Watanabe; Takafumi Suda; Kingo Chida
Related Documents :
11129124 - Galantamine: a review of its use in alzheimer's disease.
23742804 - Psychopathology and psychosocial adjustment in patients with hiv-associated lipodystrophy.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2008-03-29
Journal Detail:
Title:  Pulmonary pharmacology & therapeutics     Volume:  21     ISSN:  1094-5539     ISO Abbreviation:  Pulm Pharmacol Ther     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-07-21     Completed Date:  2008-12-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9715279     Medline TA:  Pulm Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  663-7     Citation Subset:  IM    
Affiliation:
The Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adult
Aged
Asthma / drug therapy*
Beclomethasone / administration & dosage,  therapeutic use*
Breath Tests
Budesonide / administration & dosage,  therapeutic use
Cross-Over Studies
Drug Administration Schedule
Female
Forced Expiratory Volume / drug effects
Glucocorticoids / administration & dosage,  therapeutic use*
Humans
Male
Middle Aged
Nitric Oxide / metabolism*
Quality of Life
Chemical
Reg. No./Substance:
0/Glucocorticoids; 10102-43-9/Nitric Oxide; 4419-39-0/Beclomethasone; 51333-22-3/Budesonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of oxygen-response times of phthalocyanine-based crystalline paramagnetic spin probes for...
Next Document:  The ribophorin I from Penaeus monodon shrimp: cDNA cloning, expression and phylogenetic analysis.